Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Good day everyone. My name is Megan and I will be your conference operator today. At this time, I would like to welcome you to the Kymera Therapeutics Fourth Quarter 2024 Results Call. [Operator ...

FRONTIER 2 included a range of JNJ-2113 doses, with the most effective (100 mg given twice-daily) achieving a 76% PASI 75 response – 78.6% clearance of psoriasis skin lesions – at 52 weeks.

In BE RADIANT bimekizumab performed better than Cosentyx at achieving complete clearance of skin lesions – known as a PASI 100 response ... marketed IL-23 drug Skyrizi (risankizumab) also ...

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

Baseline Psoriasis Activity Skin Index (PASI) and Physician Global Assessment scores were higher in the induction group, indicative of greater disease severity. The researchers observed ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Policia nuk bën të qartë dinamikën e sherrit, ndërsa vetë Çipa pretendon se ditën e djeshme ndërsa ecte me automjet në zonën ku po ndërton linjën elektrike i kanë dalë para dy persona dhe i kanë ...